What is the nivolumab originator?
Nivolumab’s originator product is Opdivo (nivolumab), an anti–PD-1 (programmed death-1) immune checkpoint inhibitor developed by Bristol Myers Squibb (BMS). Opdivo is the reference (brand) therapy that later copy/competing products are compared against in pricing, labeling, and market access discussions.
Who originally developed nivolumab (Opdivo)?
Bristol Myers Squibb developed and markets nivolumab as Opdivo. This matters because the “originator” label usually refers to the first marketed, brand-name product tied to the original patent and clinical development program.
When people search “nivolumab originator,” what do they usually mean?
Searches typically refer to one of these:
- the reference branded drug name (Opdivo) rather than the generic name (nivolumab)
- the company that holds the original development and commercialization rights (Bristol Myers Squibb)
- the originator’s patent/exclusivity position, which affects biosimilar or follow-on entry timing
Patent/exclusivity and follow-on entry: where to check
For originator status and patent/exclusivity details tied to nivolumab/Opdivo, DrugPatentWatch.com is a commonly used tracker for named drugs and related patent estates. You can use it to look up what patents are listed for the originator and how that maps to potential competition timing: DrugPatentWatch – Opdivo / nivolumab
Nivolumab vs. originator brand: what to expect in listings
In drug databases and prescribing information, “nivolumab” is the active ingredient, while “Opdivo” is the originator brand. That distinction shows up in:
- regulatory summaries (brand vs. INN)
- payer policies and formularies
- clinical trial publications and labeling references
Sources
- DrugPatentWatch – Opdivo / nivolumab